Total Payments
$1.0M
2024 Payments
$131,434
Companies
34
Transactions
1,315
Medicare Patients
6,563
Medicare Billing
$1.3M
Payment Breakdown by Category
Other$761,552 (74.3%)
Travel$112,799 (11.0%)
Consulting$112,456 (11.0%)
Food & Beverage$35,617 (3.5%)
Research$2,486 (0.2%)
Education$338.22 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $761,552 | 270 | 74.3% |
| Travel and Lodging | $112,799 | 374 | 11.0% |
| Consulting Fee | $112,456 | 40 | 11.0% |
| Food and Beverage | $35,617 | 603 | 3.5% |
| Unspecified | $2,486 | 4 | 0.2% |
| Education | $338.22 | 24 | 0.0% |
Payments by Type
General
$1.0M
1,311 transactions
Research
$2,486
4 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Actelion Pharmaceuticals US, Inc. | $668,566 | 687 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $288,366 | 359 | $0 (2024) |
| Merck Sharp & Dohme LLC | $22,011 | 45 | $0 (2024) |
| Genentech USA, Inc. | $16,627 | 41 | $0 (2020) |
| United Therapeutics Corporation | $9,140 | 47 | $0 (2024) |
| Johnson & Johnson Health Care Systems Inc. | $7,249 | 8 | $0 (2024) |
| Astellas Pharma US Inc | $5,503 | 16 | $0 (2019) |
| Actelion Pharmaceuticals, Ltd | $2,080 | 16 | $0 (2020) |
| E.R. Squibb & Sons, L.L.C. | $1,159 | 1 | $0 (2023) |
| Mylan Specialty L.P. | $815.70 | 2 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $131,434 | 145 | Actelion Pharmaceuticals US, Inc. ($90,844) |
| 2023 | $147,521 | 130 | Actelion Pharmaceuticals US, Inc. ($115,934) |
| 2022 | $121,291 | 109 | Actelion Pharmaceuticals US, Inc. ($91,640) |
| 2021 | $51,219 | 46 | Actelion Pharmaceuticals US, Inc. ($43,888) |
| 2020 | $55,909 | 73 | Actelion Pharmaceuticals US, Inc. ($41,773) |
| 2019 | $162,632 | 216 | Actelion Pharmaceuticals US, Inc. ($107,730) |
| 2018 | $124,768 | 275 | Bayer HealthCare Pharmaceuticals Inc. ($58,520) |
| 2017 | $230,475 | 321 | Actelion Pharmaceuticals US, Inc. ($125,246) |
All Payment Transactions
1,315 individual payment records from CMS Open Payments — Page 3 of 53
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/03/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug) | Travel and Lodging | In-kind items and services | $322.94 | General |
| Category: Cardiology | ||||||
| 10/03/2024 | Merck Sharp & Dohme LLC | WINREVAIR (Biological) | Travel and Lodging | In-kind items and services | $176.65 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/03/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug) | Food and Beverage | In-kind items and services | $150.00 | General |
| Category: Cardiology | ||||||
| 10/03/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug) | Food and Beverage | In-kind items and services | $60.00 | General |
| Category: Cardiology | ||||||
| 10/03/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug) | Food and Beverage | In-kind items and services | $50.00 | General |
| Category: Cardiology | ||||||
| 10/03/2024 | Merck Sharp & Dohme LLC | WINREVAIR (Biological) | Food and Beverage | In-kind items and services | $26.69 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/03/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug) | Food and Beverage | In-kind items and services | $15.00 | General |
| Category: Cardiology | ||||||
| 10/01/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $740.00 | General |
| 09/30/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug) | Travel and Lodging | In-kind items and services | $439.00 | General |
| Category: Cardiology | ||||||
| 09/26/2024 | Actelion Pharmaceuticals US, Inc. | — | Food and Beverage | In-kind items and services | $55.16 | General |
| 09/25/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug), OPSUMIT | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,725.00 | General |
| Category: Cardiology | ||||||
| 09/23/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug), OPSUMIT | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,363.00 | General |
| Category: Cardiology | ||||||
| 09/20/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug) | Travel and Lodging | In-kind items and services | $865.71 | General |
| Category: Cardiology | ||||||
| 09/19/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug), OPSUMIT | Food and Beverage | In-kind items and services | $120.69 | General |
| Category: Cardiology | ||||||
| 09/19/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug), OPSUMIT | Food and Beverage | In-kind items and services | $14.38 | General |
| Category: Cardiology | ||||||
| 08/30/2024 | Abbott Laboratories | CARDIOMEMS (Device) | Food and Beverage | In-kind items and services | $139.16 | General |
| Category: Heart Failure | ||||||
| 08/23/2024 | Bayer Healthcare Pharmaceuticals Inc. | Adempas (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,614.00 | General |
| Category: Cardio-pulmonary | ||||||
| 08/21/2024 | Actelion Pharmaceuticals US, Inc. | — | Food and Beverage | In-kind items and services | $132.29 | General |
| 08/20/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $108.42 | General |
| Category: IMMUNOLOGY | ||||||
| 08/16/2024 | Bayer Healthcare Pharmaceuticals Inc. | Adempas (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,614.00 | General |
| Category: Cardio-pulmonary | ||||||
| 08/15/2024 | Actelion Pharmaceuticals US, Inc. | — | Food and Beverage | In-kind items and services | $129.05 | General |
| 08/15/2024 | Bayer Healthcare Pharmaceuticals Inc. | Adempas (Drug) | Food and Beverage | In-kind items and services | $119.70 | General |
| Category: Cardio-pulmonary | ||||||
| 08/14/2024 | Bayer Healthcare Pharmaceuticals Inc. | Adempas (Drug) | Food and Beverage | In-kind items and services | $119.70 | General |
| Category: Cardio-pulmonary | ||||||
| 08/13/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug), OPSUMIT | Travel and Lodging | In-kind items and services | $455.26 | General |
| Category: Cardiology | ||||||
| 08/01/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug), OPSUMIT | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,363.00 | General |
| Category: Cardiology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| QUERI EXTENSION - AC-052428 USA | Actelion Pharmaceuticals US, Inc. | $1,190 | 2 |
| A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis | E.R. Squibb & Sons, L.L.C. | $1,159 | 1 |
| TRACE | Actelion Clinical Research, Inc. | $136.81 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 18 | 1,643 | 3,839 | $1.2M | $328,941 |
| 2022 | 20 | 1,472 | 3,153 | $1.0M | $278,391 |
| 2021 | 20 | 1,439 | 3,672 | $1.1M | $298,091 |
| 2020 | 26 | 2,009 | 5,422 | $832,761 | $369,306 |
Total Patients
6,563
Total Services
16,086
Medicare Billing
$1.3M
Procedure Codes
88
All Medicare Procedures & Services
88 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 192 | 986 | $301,676 | $89,748 | 29.7% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 155 | 492 | $321,962 | $80,090 | 24.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 191 | 366 | $150,978 | $46,109 | 30.5% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 49 | 648 | $136,592 | $39,158 | 28.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 254 | 405 | $123,847 | $35,042 | 28.3% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 66 | 68 | $27,244 | $6,683 | 24.5% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2023 | 59 | 60 | $15,900 | $4,306 | 27.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 26 | 26 | $15,429 | $4,024 | 26.1% |
| 94729 | Test to examine how well the lungs exchange gases | Office | 2023 | 97 | 102 | $15,096 | $4,021 | 26.6% |
| 94726 | Test to determine lung volumes using sensors | Office | 2023 | 96 | 101 | $14,544 | $3,793 | 26.1% |
| 90677 | Pneumococcal conjugate vaccine, 20 valent (pcv20), for intramuscular use | Office | 2023 | 13 | 13 | $13,975 | $3,668 | 26.2% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 21 | 22 | $12,980 | $2,960 | 22.8% |
| 94618 | Test for exercise-induced lung stress | Office | 2023 | 87 | 91 | $8,842 | $2,141 | 24.2% |
| 94010 | Test to measure expiratory airflow and volume | Office | 2023 | 98 | 104 | $10,088 | $1,981 | 19.6% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 126 | 231 | $4,256 | $1,940 | 45.6% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 59 | 60 | $5,414 | $1,716 | 31.7% |
| 71046 | X-ray of chest, 2 views | Office | 2023 | 41 | 51 | $4,297 | $1,190 | 27.7% |
| G0009 | Administration of pneumococcal vaccine | Office | 2023 | 13 | 13 | $1,170 | $371.80 | 31.8% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 202 | 634 | $414,002 | $109,264 | 26.4% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 116 | 912 | $191,520 | $49,488 | 25.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 165 | 266 | $109,592 | $33,315 | 30.4% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 161 | 354 | $107,616 | $27,509 | 25.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 192 | 288 | $87,840 | $25,745 | 29.3% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 56 | 61 | $24,278 | $6,308 | 26.0% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 32 | 32 | $18,880 | $4,763 | 25.2% |
About Dr. John Mcconnell, M.D
Dr. John Mcconnell, M.D is a Pulmonary Disease healthcare provider based in Louisville, Kentucky. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/11/2006. The National Provider Identifier (NPI) number assigned to this provider is 1902831761.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. John Mcconnell, M.D has received a total of $1.0M in payments from pharmaceutical and medical device companies, with $131,434 received in 2024. These payments were reported across 1,315 transactions from 34 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($761,552).
As a Medicare-enrolled provider, Mcconnell has provided services to 6,563 Medicare beneficiaries, totaling 16,086 services with total Medicare billing of $1.3M. Data is available for 4 years (2020–2023), covering 88 distinct procedure/service records.
Ad
Practice Information
- Specialty Pulmonary Disease
- Location Louisville, KY
- Active Since 07/11/2006
- Last Updated 01/26/2021
- Taxonomy Code 207RP1001X
- Entity Type Individual
- NPI Number 1902831761
Products in Payments
- UPTRAVI (Drug) $446,069
- Adempas (Drug) $283,224
- OPSUMIT (Drug) $54,526
- OPSUMIT MACITENTAN (Drug) $20,641
- Esbriet (Biological) $16,526
- WINREVAIR (Biological) $11,585
- TYVASO (Drug) $7,647
- CRESEMBA (Drug) $5,003
- BOSENTAN (Drug) $1,508
- ORENITRAM (Drug) $837.73
- Yupelri (Drug) $815.70
- TREPROSTINIL (Drug) $383.66
- TRELEGY ELLIPTA (Drug) $231.45
- FLOWTRIEVER CATHETER, S (Device) $231.35
- Genosyl (Drug) $218.53
- BlastX (Device) $199.50
- GIAPREZA (Drug) $176.58
- OFEV (Drug) $172.33
- REMODULIN (Drug) $151.09
- NUCALA (Biological) $143.50
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pulmonary Disease Doctors in Louisville
Harold Haller, Md, MD
Pulmonary Disease — Payments: $397,803
Pulmonary Disease $397,803
Kenneth Anderson, Md, MD
Pulmonary Disease — Payments: $16,989
Pulmonary Disease $16,989
Dr. Edwin Carmouche, Md, MD
Pulmonary Disease — Payments: $15,169
Pulmonary Disease $15,169
Dr. Zaka Khan, Md, MD
Pulmonary Disease — Payments: $15,042
Pulmonary Disease $15,042
Dr. Allan Ramirez, M.d, M.D
Pulmonary Disease — Payments: $12,934
Pulmonary Disease $12,934
Mr. Timothy Killeen, M.d, M.D
Pulmonary Disease — Payments: $7,955
Pulmonary Disease $7,955